VMAT-2 Inhibitors Market Size, Share, and Industry Analysis, By Drug (Tetrabenazine, Deutetrabenazine, Valbenazine, and Others), By Product Type (Branded and Generics), By Indication (Tardive Dyskinesia, Huntington's Disease, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The global VMAT-2 inhibitors market is witnessing significant growth due to the increasing incidence of neurodegenerative diseases and demand for targeted treatment. Vesicular monoamine transporter type 2 (VMAT2) inhibitors are the drug class used to deplete neuroactive peptides such as dopamine in nerve terminals in conditions such as chorea associated with Huntington's disease (HD) or in tardive dyskinesia (TD). VMAT2 inhibitors block the transport of dopamine, thus leading to a reduction in the amount of dopamine available for release in the synapse. This depletion helps to reduce the involuntary movements characteristic of hyperkinetic disorders.

• For instance, as per the data published by the Rare Disease Advisor Report, a systematic review of 13 incidence studies was performed in 2022, and the estimated pooled global prevalence of Huntington's disease was 4.88 per 100,000 persons. Thus, treating these rare conditions in the population and maintaining patients' quality of life and functional independence is expected to propel the adoption of VMAT-2 inhibitors & propel the market growth.

Additionally, the presence of key players in the market with strategic activities to develop and commercialize innovative treatment products, and launch generic versions of the drugs to bolster the market growth.

VMAT-2 Inhibitors Market Driver

Strategic Collaboration Between Key Players to Drive Market Growth

The increasing collaboration between the key players to facilitate product entry into emerging markets to enhance global accessibility is driving the growth of the VMAT-2 inhibitors market. This collaboration helps to expand the product's presence in various regions with evolving regulatory frameworks and varying healthcare access. This allows the adoption of novel VMAT-2 inhibitor treatment for tardive dyskinesia and Huntington's disease and offers better patient outcomes in the untapped regions.

• For instance, in February 2024, Teva Pharmaceutical Industries Ltd. partnered with Jiangsu Nhwa Pharmaceutical Co., Ltd for the marketing and distribution of AUSTEDO in China. This partnership intends to increase patients' access to AUSTEDO across China for the treatment of Huntington's disease (HD) and tardive dyskinesia (TD).

Estimated Huntington's Disease Prevalence by Geographic Region, 2022 (Per million Population)

According to the Rare Disease Advisor 2022 report, the highest prevalence of HD was observed in North America, 8.87 in 100,000 population.

VMAT-2 Inhibitors Market Restraint

Adverse Reactions Associated with the Drugs to Hamper the Market Growth

The long-term treatment of VMAT-2 inhibitors, such as deutetrabenazine, has severe side effects when used to treat tardive dyskinesia and chorea associated with Huntington's disease. The adverse effects noted were headache, somnolence, nausea, anxiety, fatigue, dry mouth, and diarrhea. Moroever, many studies were performed to analyze the safety of the VMAT-2 inhibitors. 

• For instance, as per the study published in Springer Nature's journal, an open-label, single-arm, two-cohort study was conducted at 37 sites in the U.S, Canada, and Australia. The study was performed on 119 patients, of whom 100 patients completed more than 1 year of treatment. The common adverse events in more than 4.0% included somnolence, depression, anxiety, insomnia, and akathisia. Also, suicidality and Parkinsonism were observed.

Such side effects associated with the treatment discourage patients from opting for advanced treatments and thus negatively impact the adoption and market expansion.

VMAT-2 Inhibitors Market Opportunity

In recent years, the increasing expenditure in research and development is expected to expand the number of pipeline candidates for VMAT-2 inhibitors for the treatment of certain neurological and neuropsychiatric conditions.

Additionally, key players in the market are focusing on initiating new pipeline studies to develop new drugs for the treatment of neurological conditions, which is expected to propel the growth of the market during the forecast period.

• For instance, in March 2025, Neurocrine Biosciences, Inc. initiated a Phase 1 clinical study for NBI-1140675. It is an oral, selective second-generation small molecule VMAT-2 inhibitor, developed for the treatment of neurological and neuropsychiatric conditions. Such clinical study initiatives are expected to boost the growth of the market. 

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries/ Regions, 2024
• Key Industry Developments (Mergers, Acquisitions, Collaborations, etc.)
• Pipeline Analysis, By Key Players
• Regulatory & Reimbursement Scenario, By Key Countries/ Regions
• Economic Cost Burden for the Treatment of Key Diseases

Segmentation

Analysis by Drug 

By drug, the market is divided into tetrabenazine, deutetrabenazine, valbenazine, and others.

Valbenazine holds a significant share of the market and is expected to grow with a significant CAGR during the forecast period. The growth of the segment is augmented by the increasing incidence of Huntington's disease and tardive dyskinesia, increased the demand for these drugs. Moreover, the focus of key players is to receive regulatory approvals and product launches to boost the segment's growth in the market. 

• For instance, in August 2023, Neurocrine Biosciences, Inc. announced the approval of INGREZZA (valbenazine) capsules by the U.S. Food and Drug Administration (FDA). It is a once-daily capsule used to treat adults with chorea associated with Huntington's disease.

Analysis by Product Type 

By product type, the market is divided into branded and generics.

The generics segment is expected to grow significantly during the forecasted timeframe. The generic drugs are affordable and effective treatment options for the majority of the population, as they serve as alternatives to the branded counterparts with less cost. The growth of the segment is attributed to the increasing focus of pharmaceutical companies to launch generic versions of branded VMAT-2 inhibitors. 

• In May 2022, Lupin resolved a patent dispute with Teva Pharmaceutical Industries Ltd for AUSTEDO (deutetrabenazine). Under this settlement agreement, Lupin received the license to sell generic deutetrabenazine from April 2033 or earlier.

Analysis by Indication

By indication, the market is divided into tardive dyskinesia, Huntington’s disease, and others.

The tardive dyskinesia segment held a substantial portion of the market. The growth of the segment is driven by the increasing prevalence of tardive dyskinesia and awareness programs associated with it. Such scenarios increase the adoption of the treatment available to treat the condition and maintain the patient's life. Furthermore, increasing approvals for VMAT-2 inhibitors for the treatment of tardive dyskinesia are expected to propel the segment's growth in the market.

• In June 2022, Mitsubishi Tanabe Pharma Corporation announced the launch of DYSVAL capsules 40mg (generic name: valbenazine) in Japan. It is the VMAT-2 inhibitor for the treatment of tardive dyskinesia in Japan.

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies held a significant share of the market. The segment's dominance is attributable to the fact that the majority of the medications for the treatment can only be prescribed after thorough examinations by trained medical professionals at these institutions. 

Also increasing number of prescriptions of VMAT-2 inhibitors by the medical practitioners, to increase the distribution of these drugs via hospital pharmacy channels.

• For instance, in December 2024, Neurology Clinical Practice reported that Medicare prescription volumes for the VMAT-2 inhibitors deutetrabenazine and valbenazine increased annually in the U.S. from 2017 to 2020. Neurologists’ primary prescribers of deutetrabenazine, accounting for 35.2% of prescriptions, while psychiatrists were the leading prescribers for valbenazine, accounting for an estimated 42.3% of the prescriptions. Such an increased volume of prescriptions by the practitioners is expected to boost the segment's growth in the market.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for a dominant share of the global VMAT-2 Inhibitors market in 2024. The rising prevalence of neurodegenerative diseases and neurological conditions, as well as the presence of advanced healthcare facilities for early diagnosis and treatment, is boosting the region's growth in the market. 

Additionally, the presence of key pharma companies with high research expenditure and product launches boosts the market growth.

• For instance, in June 2025, Neurocrine Biosciences, Inc. announced KINECT-HD study results. The new patient-reported significant reductions in both cognitive and motor-related burdens with once-daily INGREZZA (valbenazine) capsules in the adults treated for Huntington's disease chorea. 

Europe has a considerable share of the VMAT-2 Inhibitors market. The rising prevalence of Huntington's disease and the presence of adequate healthcare facilities for diagnosis and treatment are expected to propel the region's growth in the market.

• For instance, as per the data published by Rare Disease Advisor, an estimated prevalence of HD in Europe is 6.37 per 100,000 persons in 2022. Such numbers increase the demand for approved treatment and thus boost the market growth in the region.

Moreover, the Asia Pacific is expected to grow with a significant CAGR during the forecast period. Increasing focus of healthcare providers to offer adequate and effective treatment for better patient outcomes, and the presence of key generic drug manufacturers with affordable drugs to increase accessibility and reduce treatment costs. Such factors boost market growth in the Asia Pacific region.

Key Players Covered

The global VMAT-2 inhibitors market is highly consolidated, with a small number of group and standalone providers. 

The report includes the profiles of the following key players:

• Teva Pharmaceutical Industries Ltd. (Israel)
• H. Lundbeck A/S (Denmark)
• Bausch Health Companies Inc. (Canada)
• Neurocrine Biosciences, Inc. (U.S.)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Dr. Reddy's Laboratories Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)

Key Industry Developments

• In September 2023, Neurocrine Biosciences, Inc., announced that the New Drug Application (NDA) for INGREZZA (valbenazine) oral granules, a new sprinkle formulation, was accepted by the U.S. Food and Drug Administration (FDA).
• In February 2023, Teva Pharmaceutical Industries Ltd. received U.S. Food and Drug Administration approval for AUSTEDOXR (deutetrabenazine) extended-release tablets. The new once-daily formulation is used to treat adults for tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD).